Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Van Rijt, Willem G ^a   Nieuwenhuijs Moeke, Gertrude J ^a   Van Goor, Harry ^a   Ottens, Petra J ^a   Ploeg, Rutger J ^b   Leuvenink, Henri G D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ARA290; Erythropoietin; Ischemia reperfusion injury; Pyroglutamate helix B surface peptide; Renal transplantation; Renoprotection

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ARA 290; ERYTHROPOIETIN; KIDNEY INJURY MOLECULE 1; MESSENGER RNA; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ALPHA SMA GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY ISCHEMIA; KIM 1 GENE; MALE; NEPHRITIS; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REPERFUSION INJURY; THERAPY DELAY; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANIMALS; BASE SEQUENCE; DNA PRIMERS; INFLAMMATION; KIDNEY; MALE; OLIGOPEPTIDES; RATS; RATS, INBRED LEW; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84887366388     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-286     Document Type: Article

References (24)

1. Snoeijs MG, Winkens B, Heemskerk MB, Hoitsma AJ, Christiaans MH, Buurman WA, van Heurn LW. Kidney transplantation from donors after cardiac death: a 25-year experience. Transplantation 2010, 90:1106-1112. 10.1097/TP.0b013e3181f83b0b, 20861804.
2. Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant 2011, 11:2279-2296. 10.1111/j.1600-6143.2011.03754.x, 3280444, 21929642.
3. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006, 69:1806-1813. 10.1038/sj.ki.5000356, 16598197.
4. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004, 101:14907-14912. 10.1073/pnas.0406491101, 522054, 15456912.
5. Hu L, Yang C, Zhao T, Xu M, Tang Q, Yang B, Rong R, Zhu T. Erythropoietin ameliorates renal ischemia and reperfusion injury via inhibiting tubulointerstitial inflammation. J Surg Res 2012, 176:260-266. 10.1016/j.jss.2011.06.035, 21816412.
6. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004, 15:2115-2124. 10.1097/01.ASN.0000135059.67385.5D, 15284297.
7. Su KH, Shyue SK, Kou YR, Ching LC, Chiang AN, Yu YB, Chen CY, Pan CC, Lee TS. Beta common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 2011, 226:3330-3339. 10.1002/jcp.22678, 21321940.
8. Oba S, Suzuki E, Nishimatsu H, Kumano S, Hosoda C, Homma Y, Hirata Y. Renoprotective effect of erythropoietin in ischemia/reperfusion injury: possible roles of the Akt/endothelial nitric oxide synthase-dependent pathway. Int J Urol 2012, 19:248-255. 10.1111/j.1442-2042.2011.02920.x, 22126194.
9. Schlaich MP, Schmitt D, Ott C, Schmidt BM, Schmieder RE. Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. J Hypertens 2008, 26:110-116. 10.1097/HJH.0b013e3282f1a93e, 18090547.
10. Juncos LA, Garvin J, Carretero OA, Ito S. Flow modulates myogenic responses in isolated microperfused rabbit afferent arterioles via endothelium-derived nitric oxide. J Clin Invest 1995, 95:2741-2748. 10.1172/JCI117977, 295958, 7769114.
11. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000, 95:2983-2989.
12. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008, 264:405-432. 10.1111/j.1365-2796.2008.02024.x, 19017170.
13. Aydin Z, Mallat MJ, Schaapherder AF, van Zonneveld AJ, van Kooten C, Rabelink TJ, de Fijter JW. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant 2012, 12:1793-1800. 10.1111/j.1600-6143.2012.04019.x, 22429395.
14. Hafer C, Becker T, Kielstein JT, Bahlmann E, Schwarz A, Grinzoff N, Drzymala D, Bonnard I, Richter N, Lehner F, Klempnauer J, Haller H, Traeder J, Fliser D. High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney Int 2012, 81:314-320. 10.1038/ki.2011.349, 22012130.
15. Martinez F, Kamar N, Pallet N, Lang P, Durrbach A, Lebranchu Y, Adem A, Barbier S, Cassuto-Viguier E, Glowaki F, Le Meur Y, Rostaing L, Legendre C, Hermine O, Choukroun G, NeoPDGF Study Investigators High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF Study. Am J Transplant 2010, 10:1695-1700. 10.1111/j.1600-6143.2010.03142.x, 20642691, NeoPDGF Study Investigators.
16. Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol 2012, 7:1498-1506. 10.2215/CJN.01360212, 3430945, 22745272.
17. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008, 105:10925-10930. 10.1073/pnas.0805594105, 2504825, 18676614.
18. Patel NS, Kerr-Peterson HL, Brines M, Collino M, Rogazzo M, Fantozzi R, Wood EG, Johnson FL, Yaqoob MM, Cerami A, Thiemermann C. The delayed administration of pHBSP, a novel non-erythropoietic analogue of erythropoietin, attenuates acute kidney injury. Mol Med 2012, 18:719-727. 3388125, 22415011.
19. Van Rijt WG, Nieuwenhuijs-Moeke GJ, Van Goor H, Jespersen B, Ottens PJ, Ploeg RJ, Leuvenink HG. ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury. J Transl Med 2013, 11:9-5876-11-9.
20. Ishii Y, Sawada T, Murakami T, Sakuraoka Y, Shiraki T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant 2011, 26:1157-1162. 10.1093/ndt/gfq601, 20935018.
21. Solling C, Christensen AT, Krag S, Frokiaer J, Wogensen L, Krog J, Tonnesen EK. Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand 2011, 55:185-195. 10.1111/j.1399-6576.2010.02369.x, 21226860.
22. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002, 62:237-244. 10.1046/j.1523-1755.2002.00433.x, 12081583.
23. Yamasowa H, Shimizu S, Inoue T, Takaoka M, Matsumura Y. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. J Pharmacol Exp Ther 2005, 312:153-159.
24. Villanueva S, Cespedes C, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 2006, 290:R861-R870.